Resumes
Resumes
Huifeng Niu Phones & Addresses
-
Southborough, MA
-
1 Earhart St UNIT 709, Cambridge, MA 02141 (908) 227-2783
-
Park City, IL
-
60 Haven Ave #6B, New York, NY 10032
-
2050 Wood Rd, Scotch Plains, NJ 07076 (212) 410-1851
-
Orangeburg, SC
-
Union, NJ
Publications
Us Patents
Method For Inhibiting Proliferation Of Tumor Cells
View pageUS Patent:
20080207563, Aug 28, 2008
Filed:
Feb 21, 2008
Appl. No.:
12/034694
Inventors:
Huifeng Niu - Scotch Plains NJ, US
International Classification:
A61K 31/661
C12N 5/00
A61K 31/517
A61K 31/496
A61P 35/00
A61K 31/397
A61K 31/5377
C12N 5/00
A61K 31/517
A61K 31/496
A61P 35/00
A61K 31/397
A61K 31/5377
US Classification:
514 94, 435375, 5142664, 5142102, 5142358, 51425405
Abstract:
Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.
Cloning And Uses Of The Genetic Locus Bcl-6
View pageUS Patent:
20010010922, Aug 2, 2001
Filed:
Jun 30, 1998
Appl. No.:
09/107058
Inventors:
RICCARDO DALLA-FAVERA - NEW YORK NY, US
HUIFENG NIU - NEW YORK NY, US
HUIFENG NIU - NEW YORK NY, US
International Classification:
A01N037/18
A61K038/00
C12Q001/68
A61K038/16
G01N033/574
A61K039/395
A61K038/00
C12Q001/68
A61K038/16
G01N033/574
A61K039/395
US Classification:
435/007230, 514/007000, 424/130100, 514/002000
Abstract:
This invention provides an isolated vertebrate nucleic acid molecule the bcl-6 locus. This invention also provides an isolated human nucleic acid molecule of bcl-6 locus. This invention further provides a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic acid molecule of bcl-6 locus. This invention provides an isolated vertebrate nucleic acid molecule of bcl-6 operatively linked to a promoter of RNA transcription. This invention provides a vector which comprises the nucleic acid molecule of bcl-6 locus. This invention provides a host vector system for the production of a polypeptide encoded by bcl-6 locus, which comprises the vector of bcl-6 locus in a suitable host. This invention provides a polypeptide encoded by the isolated vertebrate nucleic acid molecule of bcl-6 locus. This invention provides an antibody capable of binding to polypeptide encoded by bcl-6 locus. This invention provides an antagonist capable of blocking the expression of the polypeptide encoded by bcl-6. This invention provides an antisense molecule capable of hybridizing to the nucleic acid molecule of bcl-6. This invention provides an assay for non-Hodgkin's lymphoma, a method for screening putative therapeutic agents for treatment of non-Hodgkin's lymphoma and a method for diagnosing B-cell lymphoma in a subject. Finally, this invention provides a method of treating a subject with non-Hodgkin's lymphoma.
Cancer Treatment Methods Based On Tp53 Mutation Status And Hypermutation Status
View pageUS Patent:
20210267980, Sep 2, 2021
Filed:
Jun 18, 2019
Appl. No.:
17/252400
Inventors:
- Osaka, JP
Kenichi IWAI - Kanagawa, JP
Tadahiro NAMBU - Kanagawa, JP
Kazunori YAMANAKA - Kanagawa, JP
Kentaro OTAKE - Kanagawa, JP
Huifeng NIU - Cambridge MA, US
Hyunjin SHIN - Cambridge MA, US
Erik Michael KOENIG - Cambridge MA, US
Kenichi IWAI - Kanagawa, JP
Tadahiro NAMBU - Kanagawa, JP
Kazunori YAMANAKA - Kanagawa, JP
Kentaro OTAKE - Kanagawa, JP
Huifeng NIU - Cambridge MA, US
Hyunjin SHIN - Cambridge MA, US
Erik Michael KOENIG - Cambridge MA, US
International Classification:
A61K 31/519
C12Q 1/6886
A61P 35/00
C12Q 1/6886
A61P 35/00
Abstract:
The present disclosure relates to methods useful for determining whether to treat cancer in a patient, and treating cancer in a patient, by administering a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof.
Biomarkers Of Response To Selective Inhibitors Of Aurora A Kinase
View pageUS Patent:
20190194750, Jun 27, 2019
Filed:
Jun 24, 2016
Appl. No.:
15/741408
Inventors:
- Cambridge MA, US
Huifeng Niu - Cambridge MA, US
Hyunjin Shin - Brookline MA, US
Zhongfa Zhang - Waltham MA, US
Huifeng Niu - Cambridge MA, US
Hyunjin Shin - Brookline MA, US
Zhongfa Zhang - Waltham MA, US
International Classification:
C12Q 1/6883
C12Q 1/686
A61K 31/55
A61P 35/00
C12Q 1/686
A61K 31/55
A61P 35/00
Abstract:
Disclosed herein are WNT and Hippo pathway markers associated with sensitivity to treatment with Aurora A kinase inhibitors. Claimed genes include LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XP01, ROR2, CCND1 & CTNNB1 (WNT pathway) and AMOT, DVL2, LATS1, LATS2, MOB1 B, NPHP4, TJP1, TJP2, WCC1, WWTR1 & YAP1 (Hippo pathway). Sensitivity to treatment with an Aurora A kinase inhibitor is observed when the aforementioned markers have mutations in tumor cells. Compositions and methods are provided to assess marker genes to predict response to Aurora Kinase A inhibition treatment and for patient selection.
Bispecific Antibodies Specific For Fap And Dr5, Antibodies Specific For Dr5 And Methods Of Use
View pageUS Patent:
20190062453, Feb 28, 2019
Filed:
Mar 6, 2018
Appl. No.:
15/913713
Inventors:
- Schlieren, CH
Sherif Daouti - Totowa NJ, US
Ningping Feng - Richmond Hill, CA
Claudia Ferrara Koller - Zug, CH
Guy Georges - Habach, DE
Sandra Grau-Richards - Birmensdorf, CH
Ralf Hosse - Cham, CH
Christian Klein - Bonstetten, CH
Maximiliane Koenig - Pullach, DE
Joerg Moelleken - Muenchen, DE
Ekkehard Moessner - Kreuzlingen, CH
Huifeng Niu - Scotch Plains NJ, US
Kathryn E. Packman - Newton MA, US
Valeria Runza - Penzberg, DE
Stefan Seeber - Sindelsdorf, DE
Pablo Umana - Wollerau, CH
lnja Waldhauer - Urdorf, CH
Huisheng Wang - Edison NJ, US
Barbara Weiser - Sindelsdorf, DE
Sherif Daouti - Totowa NJ, US
Ningping Feng - Richmond Hill, CA
Claudia Ferrara Koller - Zug, CH
Guy Georges - Habach, DE
Sandra Grau-Richards - Birmensdorf, CH
Ralf Hosse - Cham, CH
Christian Klein - Bonstetten, CH
Maximiliane Koenig - Pullach, DE
Joerg Moelleken - Muenchen, DE
Ekkehard Moessner - Kreuzlingen, CH
Huifeng Niu - Scotch Plains NJ, US
Kathryn E. Packman - Newton MA, US
Valeria Runza - Penzberg, DE
Stefan Seeber - Sindelsdorf, DE
Pablo Umana - Wollerau, CH
lnja Waldhauer - Urdorf, CH
Huisheng Wang - Edison NJ, US
Barbara Weiser - Sindelsdorf, DE
Assignee:
Roche Glycart AG - Schlieren
International Classification:
C07K 16/40
C07K 16/28
C07K 16/28
Abstract:
The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Combination Of Catalytic Mtorc 1/2 Inhibitors And Selective Inhibitors Of Aurora A Kinase
View pageUS Patent:
20180117060, May 3, 2018
Filed:
Aug 7, 2017
Appl. No.:
15/670889
Inventors:
- Cambridge MA, US
Huifeng Niu - Cambridge MA, US
Huifeng Niu - Cambridge MA, US
International Classification:
A61K 31/55
A61K 31/519
A61K 45/06
A61K 31/519
A61K 45/06
Abstract:
Disclosed are methods for the treatment of proliferative disorders. Disclosed in particular, are methods for treatment of proliferative disorders such as cancer, by administering an mTORC1/2 inhibitor in combination with a selective inhibitor of Aurora A kinase. Preferred MTORC1/2 inhibitors include MLN0128 and the preferred Aurora A kinase inhibitor of the combination is ML-N8237.
Combination Of Catalytic Mtorc 1/2 Inhibitors And Selective Inhibitors Of Aurora A Kinase
View pageUS Patent:
20160271140, Sep 22, 2016
Filed:
Mar 21, 2014
Appl. No.:
14/777888
Inventors:
- Cambridge MA, US
Huifeng NIU - Cambridge MA, US
Huifeng NIU - Cambridge MA, US
International Classification:
A61K 31/55
A61K 31/519
A61K 31/519
Abstract:
Disclosed are methods for the treatment of proliferative disorders. Disclosed in particular, are methods for treatment of proliferative disorders such as cancer, by administering an mTORC1/2 inhibitor in combination with a selective inhibitor of Aurora A kinase. Preferred MTORC1/2 inhibitors include MLN0128 and the preferred Aurora A kinase inhibitor of the combination is MLN8237.
Cell Penetrating Peptides To Target Eif4E
View pageUS Patent:
20150166621, Jun 18, 2015
Filed:
Jul 5, 2013
Appl. No.:
14/411951
Inventors:
- Nutley NJ, US
Nader Fotouhi - Basking Ridge NJ, US
Yi Han - Morristown NJ, US
Wajiha Khan - Boonton NJ, US
Francesca Milletti - New York NY, US
Huifeng Niu - Scotch Plains NJ, US
Nader Fotouhi - Basking Ridge NJ, US
Yi Han - Morristown NJ, US
Wajiha Khan - Boonton NJ, US
Francesca Milletti - New York NY, US
Huifeng Niu - Scotch Plains NJ, US
International Classification:
C07K 14/47
Abstract:
The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.